{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:35:34Z","timestamp":1762673734970},"reference-count":44,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.4155\/fmc.09.53","type":"journal-article","created":{"date-parts":[[2009,8,14]],"date-time":"2009-08-14T11:06:43Z","timestamp":1250248003000},"page":"749-756","source":"Crossref","is-referenced-by-count":15,"title":["Challenges, Successes and Hopes in the Development of Novel Tb Therapeutics"],"prefix":"10.1080","volume":"1","author":[{"given":"Leonard V","family":"Sacks","sequence":"first","affiliation":[{"name":"Office of Critical Path Programs, US FDA, Room 14B 45, 5600 Fishers Lane, Rockville, MD20857, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel E","family":"Behrman","sequence":"additional","affiliation":[{"name":"Office of Critical Path Programs, US FDA, Room 14B 45, 5600 Fishers Lane, Rockville, MD20857, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2009,8,14]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14333-4"},{"key":"e_1_3_2_3_2_1","unstructured":"WHO . Global Tuberculosis control 2008 surveillance planning financing. WHO report 2008 WHO\/HTM\/TB\/2008.393."},{"key":"e_1_3_2_3_3_1","unstructured":"Centers for Disease Control and Prevention: trends in tuberculosis incidence. United States 2006. MMWR56 245\u2013250 (2007)."},{"key":"e_1_3_2_3_4_1","unstructured":"WHO . Anti-tuberculosis drug resistance in the world. Fourth global report WHO\/HTM\/TB\/2008.394."},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69573-1"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.11.6740"},{"key":"e_1_3_2_3_7_1","unstructured":"Brock T MadiganM. Biology of Microorganisms (6th Edition). Prentice Hall NJ USA (1991)."},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/jb.136.1.35-48.1978"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00526-6"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2621.1976.tb01118.x"},{"key":"e_1_3_2_3_11_1","first-page":"285","article-title":"Antibiotic treatment of tuberculosis: old problems, new solutions.","volume":"3","author":"Jain SK","year":"2008","unstructured":"Jain SK , LamichhaneG, NimmagaddaS, PomperMG, BishaiWR. Antibiotic treatment of tuberculosis: old problems, new solutions.Microbe3, 285\u2013292 (2008)","journal-title":"Microbe"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-9792(02)00089-6"},{"key":"e_1_3_2_3_13_1","first-page":"105","article-title":"The survival of Mycobacterium tuberculosis on surfaces at different relative humidities","volume":"176","author":"Kunz R","year":"1982","unstructured":"Kunz R , GundermannKC. The survival of Mycobacterium tuberculosis on surfaces at different relative humidities. Arch. Hyg. Bakteriol.176, 105\u2013115 (1982).","journal-title":"Arch. Hyg. Bakteriol."},{"key":"e_1_3_2_3_14_1","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis units 1946\u20131986, with relevant subsequent publications.","volume":"3","author":"Fox W","year":"1999","unstructured":"Fox W , EllardGA, MitchisonDA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis units 1946\u20131986, with relevant subsequent publications.Int. J. Tuberc. Lung Dis.3, S231\u2013S279 (1999).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00001307"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-76-3-112-6-397"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200308-1159OC"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530120037038"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92278-4"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.2.288"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11467-8"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1119299"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0307-266"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.0010046"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.22.12833"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/513945"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki148"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.2054"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.1004"},{"key":"e_1_3_2_3_30_1","first-page":"167","article-title":"Drug discovery for tuberculosis: bottlenecks and path forward.","volume":"86","author":"Balganesh TS","year":"2004","unstructured":"Balganesh TS , BalasubramanianV, KumarSA. Drug discovery for tuberculosis: bottlenecks and path forward.Curr. Sci.86, 167\u2013176 (2004).","journal-title":"Curr. Sci."},{"key":"e_1_3_2_3_31_1","first-page":"491","article-title":"Tuberculosis \u2013 strategies towards anti-infectives for a chronic disease.","volume":"1","author":"Barry CE","year":"2004","unstructured":"Barry CE , DuncanK. Tuberculosis \u2013 strategies towards anti-infectives for a chronic disease.Drug Discov. Today1, 491\u2013496 (2004).","journal-title":"Drug Discov. Today"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.2.183"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030466"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/35016103"},{"key":"e_1_3_2_3_35_1","first-page":"S13","article-title":"Overview of the global TB pipleline (Abstract).","volume":"12","author":"Ma Z","year":"2008","unstructured":"Ma Z . Overview of the global TB pipleline (Abstract).Int. J. Tuberc. Lung Dis.12, S13 (2008).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_3_36_1","first-page":"S14","article-title":"Update on PA-824.","volume":"12","author":"Diacon A","year":"2008","unstructured":"Diacon A , DawsonR, VenterAet al. Update on PA-824. Int. J. Tuberc. Lung Dis. 12, S14 (2008).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01204-07"},{"key":"e_1_3_2_3_38_1","unstructured":"Diacon AH PymA GrobuschMet al. Interim analysis of a double-blind placebo-controlled study with TMC207 in patients with multi-drug resistant (MDR) Tuberculosis (Abstract). Presented at: 48th Annual ICAAC. Washington DC USA. 25\u201328 October 2008."},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki319"},{"key":"e_1_3_2_3_40_1","article-title":"Phase 1 safety and pharmacokinetics of SQ109, a new diamine anti-tuberculosis drug (meeting Abstract 1128).","author":"Horwith G","year":"2007","unstructured":"Horwith G , EinckL, ProtopopovaM, NacyC. Phase 1 safety and pharmacokinetics of SQ109, a new diamine anti-tuberculosis drug (meeting Abstract 1128).Am. J. Infect. Dis. (2007).","journal-title":"Am. J. Infect. Dis."},{"key":"e_1_3_2_3_41_1","first-page":"S319","article-title":"Phase 1 clinical trial of LL-3858 (Sudoterb), a potential candidate for the treatment of MDR tuberculosis.","volume":"12","author":"Arora SK","year":"2008","unstructured":"Arora SK , AnuradhaK, AvhadAJ. Phase 1 clinical trial of LL-3858 (Sudoterb), a potential candidate for the treatment of MDR tuberculosis.Int. J. Tuberc. Lung Dis.12, S319 (2008).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.55.1.139"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2002.02779.x"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.653-657.2003"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.09.53","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:48:45Z","timestamp":1716493725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.09.53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.4155\/fmc.09.53"],"URL":"https:\/\/doi.org\/10.4155\/fmc.09.53","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}